Working… Menu

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03682770
Recruitment Status : Active, not recruiting
First Posted : September 25, 2018
Last Update Posted : March 10, 2021
Aimmune Therapeutics, Inc.
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : October 16, 2020
Estimated Study Completion Date : October 6, 2021